Today, a new approach is giving patients and their physicians reason to hope. Moffitt Cancer Center has expanded its ...

In vivo platform enables efficient, site-specific CAR gene insertion under control of an endogenous T cell promoter, producing functional CART ...

A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ...

A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also cumbersome and ...

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Explore the breakthrough of new CAR-T cell therapy for glioblastoma, offering hope against one of the deadliest brain cancers.

Cabaletta Bio’s CAR-T cell therapy has eliminated the overreactive B cells of two patients with an autoimmune disease without preconditioning chemotherapy, pleasing investors and analysts while ...

Outpatient CAR T therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole. Dr. Olalekan O. Oluwole, an attending ...